Solving Today’s Problems

Executive Team

We are dedicated to improving the lives of those suffering from neurodegenerative diseases. We solve problems with rigorous science and innovative therapies. We have assembled a team with deep scientific, clinical, commercial, and leadership experience and expertise in medical technology and neurodegenerative diseases.

Kent Savage

Kent Savage

CEO, Co-Founder

Former President and CEO at Apollo Light Systems where he led efforts to innovate, patent and deliver specialized light therapy devices for mood and sleep disorders to more than 300,000 patients (sold to Philips Respironics).
Dan Adams

Dan Adams

Science Officer, Co-Founder

At the forefront of research in circadian regulation and light therapy advances. 25+ years of commercial neuroscience and medical device experience. Former head of research for Apollo Light Systems and senior scientist for Philips.
Karl Kieburtz, MD, MPH

Karl Kieburtz, MD, MPH

Medical Officer

 Renowned neurologist and former chair of the FDA peripheral and central nervous system advisory Committee and former VP of the American Neurological Association. Iinvolved with every treatment approved by FDA in the last 20 years.

Brett Walker

Brett Walker

Marketing Officer

Extensive experience leading product/service launches now producing over a billion dollars annually (Intel, Ancestry, Monster, VitalSmarts, Action Target). Market proficiency across multiple industries and all marketing disciplines.
Greg Schneider

Greg Schneider

Market Access

Formerly with Medtronic, Pfizer, Siemens, Wyath, Extensive drug and device market access expertise with deep experience in Medicare, VA and private coverage, coding, and payments.

Suzanne Hendrix, PhD

Suzanne Hendrix, PhD

Biostatistican

Brad Wyman, PhD

Brad Wyman, PhD

SVP, Science

Mike Drake

Mike Drake

VP Quality & Regulatory

Advisory Board

Our Clinical & Scientific Advisory board (CSAB) is comprised of leading experts in Parkinson’s disease (PD) and other neurodegenerative diseases. The board’s aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to improve the lives of people who suffer from neurodegenerative diseases. Our leadership in non-invasive specialized light therapy for neurodegenerative diseases benefits from the advice and insight of this world-class advisory board.
Robert A. Hauser, M.D., MBA

Robert A. Hauser, M.D., MBA

Ray Chaudhuri, MD

Ray Chaudhuri, MD

Joohi Jimenez-Shahed, MD

Joohi Jimenez-Shahed, MD

Dan Claassen, MD, MS

Dan Claassen, MD, MS

Rajeesh Pahwa, MD

Rajeesh Pahwa, MD

Amy Amara, MD, PhD

Amy Amara, MD, PhD

George C. Brainard, M.A., Ph.D.

George C. Brainard, M.A., Ph.D.

Charles H. Adler, M.D., Ph.D

Charles H. Adler, M.D., Ph.D

    In Memoriam of Warren Olanow

Warren Olanow, MD (1941-2024)

Warren Olanow, MD (1941-2024)

Distinguished Physician, Researcher, Colleague, Father, and Friend

 

The entire PhotoPharmics team mourns the passing of Dr. C. Warren Olanow, a pivotal figure in neurology and chairman of our Clinical and Scientific Advisory Board. Dr. Olanow’s groundbreaking work in Parkinson’s and neurodegenerative research has profoundly advanced our understanding and treatment of movement disorders. His legacy will forever inspire our mission. We extend our heartfelt condolences to his family and honor his lifelong dedication to improving patient lives.

The world is less rich in his absence.

The Cycle of Innovation, Clinical Research, and Improved Lives

For decades, our founders developed innovative specialized phototherapy devices for circadian-related neuropsychiatric disorders. They validated the new devices’ safety and efficacy in human clinical trials and delivered those innovations to and improved the lives of hundreds of

They have now applied their expertise to circadian dysregulation in neurodegenerative disease. Building on this, we have created a new platform technology and developed a safe and convenient product for Parkinson’s patients. PhotoPharmics is now validating this product in robust clinical research. After demonstrating safety and efficacy, these products will become widely available for people with Parkinson’s.

In addition to improving the lives of Parkinson’s patients, recent science and clinical evidence leads us to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s to other age-related neurodegenerative diseases. We will validate those products in clinical research, and if successful, deliver the solutions to individuals who suffer from these diseases.

WORKING TOGETHER

Join us in improving lives by supporting our innovation and participating in our clinical research.